Biosensors for prostate cancer detection

Trends Biotechnol. 2023 Oct;41(10):1248-1267. doi: 10.1016/j.tibtech.2023.04.001. Epub 2023 May 3.

Abstract

Prostate cancer (PC) is one of the most common tumors and a leading cause of mortality among men, resulting in ~375 000 deaths annually worldwide. Various analytical methods have been designed for quantitative and rapid detection of PC biomarkers. Electrochemical (EC), optical, and magnetic biosensors have been developed to detect tumor biomarkers in clinical and point-of-care (POC) settings. Although POC biosensors have shown potential for detection of PC biomarkers, some limitations, such as the sample preparation, should be considered. To tackle such shortcomings, new technologies have been utilized for development of more practical biosensors. Here, biosensing platforms for the detection of PC biomarkers such as immunosensors, aptasensors, genosensors, paper-based devices, microfluidic systems, and multiplex high-throughput platforms, are discussed.

Keywords: biomarkers; biosensors; healthcare; point of care; prostate cancer.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor
  • Biosensing Techniques* / methods
  • Electrochemical Techniques
  • Humans
  • Immunoassay
  • Male
  • Point-of-Care Systems
  • Prostatic Neoplasms* / diagnosis

Substances

  • Biomarkers, Tumor